The online version of this article (doi:10.1186/cc10356) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
MPC participated in the study design and coordination, carried out the molecular genetic studies and functional assays, and helped to draft the manuscript. VT carried out the MP number experiments and functional assays and helped to draft the manuscript. CD carried out the MP number experiments. IW and DW contributed patient samples. JT helped to draft the manuscript. CHT conceived of the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
Activated protein C (APC) induces release of microparticles (MP) from primary physiological cells, which are found in patients undergoing treatment with recombinant human APC (rhAPC) for severe sepsis. We hypothesised that APC on these circulating MPs activate endothelial protease-activated receptor 1 (PAR1) to induce anti-apoptotic and anti-inflammatory properties that can improve patient outcome.
This was an experimental study on clinical samples in an intensive care setting, and included patients with severe sepsis who fulfilled criteria for treatment with rhAPC. The number of CD13+ MPs from the patients were analysed to determine their origin. They were also quantified for endothelial protein C receptor (EPCR) and APC expression. Clinical relevance of these MPs were ascertained by comparing survival between the group receiving rhAPC (n = 25) and a control group of untreated patients (n = 25). MPs were also incubated with endothelial cells to analyse apoptotic gene expression, cytoprotection and anti-inflammatory effects.
rhAPC treatment induced a significant increase in circulating MP-associated EPCR by flow cytometry (P < 0.05) and by quantitative ELISA (P < 0.005). APC expression also showed significant increases (P < 0.05). Numerically, CD13+ MPs were higher in rhAPC-treated survivors versus non-survivors. However, the number of non-survivors was low and this was not significantly different. APC on MPs was demonstrated to induce anti-apoptotic and endothelial barrier effects through the activation of endothelial PAR1.
rhAPC treatment in patients with sepsis significantly increases circulating EPCR + MPs. These MPs were noted to express APC, which has specific anti-apoptotic and anti-inflammatory effects, with a non-significant correlative trend towards survival. This suggests that MPs could disseminate APC function and activate endothelial PAR1 at distal vascular sites.
Additional file 1:Supplementary information. Supplementary materials and methods, and figure legend [ 17, 18, 45– 48]. (DOCX 16 KB)
Additional file 2:Supplementary Figure S1. The proportion of free versus bound rhAPC on microparticles. Comparison of results obtained from patient samples to in vitro derived MPs. (TIFF 31 KB)13054_2011_9615_MOESM2_ESM.TIFF
Additional file 3:Supplementary table S1. Genes modulated by APC (free or microparticle [MP]-bound from patients). Microarray results. (DOCX 17 KB)13054_2011_9615_MOESM3_ESM.DOCX
Authors’ original file for figure 113054_2011_9615_MOESM4_ESM.tiff
Authors’ original file for figure 213054_2011_9615_MOESM5_ESM.tiff
Authors’ original file for figure 313054_2011_9615_MOESM6_ESM.tiff
Authors’ original file for figure 413054_2011_9615_MOESM7_ESM.tiff
Authors’ original file for figure 513054_2011_9615_MOESM8_ESM.tiff
Authors’ original file for figure 713054_2011_9615_MOESM9_ESM.tiff
Mostefai HA, Meziani F, Mastronardi ML, Agouni A, Heymes C, Sargentini C, Asfar P, Martinez MC, Andriantsitohaina R: Circulating microparticles from patients with septic shock exert protective role in vascular function. Am J Respir Crit Care Med 2008, 178: 1148-1155. 10.1164/rccm.200712-1835OC PubMedCrossRef
Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG, Hack CE, Sturk A: Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000, 95: 930-935. PubMed
Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J, Dignat-George F: In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999, 104: 93-102. 10.1172/JCI4985 PubMedPubMedCentralCrossRef
Berckmans RJ, Neiuwland R, Boing AN, Romijn FP, Hack CE, Sturk A: Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001, 85: 639-646. PubMed
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001 PubMedCrossRef
Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Gardlund B, Marshall JC, Rhodes A: Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008, 34: 1935-1947. 10.1007/s00134-008-1266-6 PubMedPubMedCentralCrossRef
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655. 10.1378/chest.101.6.1644 PubMedCrossRef
National Institute for Health and Clinical Excellence: Drotrecogin alfa (activated) for Severe Sepsis Technology Appraisal Guidance 84. London: National Institute for Health and Clinical Excellence; 2004. [ http://www.nice.org.uk/nicemedia/live/11546/32955/32955.pdf]
Zheng J, Chen Y, Pat B, Dell'italia LA, Tillson M, Dillon AR, Powell PC, Shi K, Shah N, Denney T, Husain A, Dell'Italia LJ: Microarray identifies extensive downregulation of noncollagen extracellular matrix and profibrotic growth factor genes in chronic isolated mitral regurgitation in the dog. Circulation 2009, 119: 2086-2095. 10.1161/CIRCULATIONAHA.108.826230 PubMedPubMedCentralCrossRef
Fukudome K, Esmon CT: Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994, 269: 26486-26491. PubMed
Lynch SF, Ludlam CA: Plasma microparticles and vascular disorders. Br J Haematol 2007, 137: 36-48. PubMed
Fujimi S, Ogura H, Tanaka H, Koh T, Hosotsubo H, Nakamori Y, Kuwagata Y, Shimazu T, Sugimoto H: Activated polymorphonuclear leukocytes enhance production of leukocyte microparticles with increased adhesion molecules in patients with sepsis. J Trauma 2002, 52: 443-448. 10.1097/00005373-200203000-00005 PubMedCrossRef
Joop K, Berckmans RJ, Nieuwland R, Berkhout J, Romijn FP, Hack CE, Sturk A: Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001, 85: 810-820. PubMed
Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH, Mostefai HA, Draunet-Busson C, Leftheriotis G, Heymes C, Martinez MC, Andriantsitohaina R: Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol 2008, 173: 1210-1219. 10.2353/ajpath.2008.080228 PubMedPubMedCentralCrossRef
Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, Kyrle PA, Weltermann A: Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007, 97: 119-123. PubMed
Soriano AO, Jy W, Chirinos JA, Valdivia MA, Velasquez HS, Jimenez JJ, Horstman LL, Kett DH, Schein RM, Ahn YS: Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med 2005, 33: 2540-2546. 10.1097/01.CCM.0000186414.86162.03 PubMedCrossRef
Bae JS, Yang L, Manithody C, Rezaie AR: The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007, 110: 3909-3916. 10.1182/blood-2007-06-096651 PubMedPubMedCentralCrossRef
Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D'Angelo A, Della Valle P, Esmon CT: Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 1998, 91: 725-727. PubMed
Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M: Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001, 29: 365-371. 10.1038/ng1201-365 PubMedCrossRef
- The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis
Cheng Hock Toh
- BioMed Central
Neu im Fachgebiet AINS
Meistgelesene Bücher aus dem Fachgebiet AINS
Mail Icon II